Cargando…

Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds

Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuclein induced synucleinopathy in heterozygous mice transgenic for human mutant A53T α-synuclein (line M83). The same was the case when cerebellar extracts from a case of multiple system atrophy with ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Macdonald, Jennifer A., Chen, John L., Masuda-Suzukake, Masami, Schweighauser, Manuel, Jaunmuktane, Zane, Warner, Thomas, Holton, Janice L., Grossman, Annabelle, Berks, Richard, Lavenir, Isabelle, Goedert, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611835/
https://www.ncbi.nlm.nih.gov/pubmed/34819144
http://dx.doi.org/10.1186/s40478-021-01291-7
_version_ 1784603368556068864
author Macdonald, Jennifer A.
Chen, John L.
Masuda-Suzukake, Masami
Schweighauser, Manuel
Jaunmuktane, Zane
Warner, Thomas
Holton, Janice L.
Grossman, Annabelle
Berks, Richard
Lavenir, Isabelle
Goedert, Michel
author_facet Macdonald, Jennifer A.
Chen, John L.
Masuda-Suzukake, Masami
Schweighauser, Manuel
Jaunmuktane, Zane
Warner, Thomas
Holton, Janice L.
Grossman, Annabelle
Berks, Richard
Lavenir, Isabelle
Goedert, Michel
author_sort Macdonald, Jennifer A.
collection PubMed
description Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuclein induced synucleinopathy in heterozygous mice transgenic for human mutant A53T α-synuclein (line M83). The same was the case when cerebellar extracts from a case of multiple system atrophy with type II α-synuclein filaments were administered intraperitoneally, intravenously or intramuscularly. We observed abundant immunoreactivity for pS129 α-synuclein in nerve cells and severe motor impairment, resulting in hindlimb paralysis and shortened lifespan. Filaments immunoreactive for pS129 α-synuclein were in evidence. A 70% loss of motor neurons was present five months after an intraperitoneal injection of assembled A53T α-synuclein or cerebellar extract with type II α-synuclein filaments from an individual with a neuropathologically confirmed diagnosis of multiple system atrophy. Microglial cells changed from a predominantly ramified to a dystrophic appearance. Taken together, these findings establish a close relationship between the formation of α-synuclein inclusions in nerve cells and neurodegeneration, accompanied by a shift in microglial cell morphology. Propagation of α-synuclein inclusions depended on the characteristics of both seeds and transgenically expressed protein. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01291-7.
format Online
Article
Text
id pubmed-8611835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86118352021-11-29 Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds Macdonald, Jennifer A. Chen, John L. Masuda-Suzukake, Masami Schweighauser, Manuel Jaunmuktane, Zane Warner, Thomas Holton, Janice L. Grossman, Annabelle Berks, Richard Lavenir, Isabelle Goedert, Michel Acta Neuropathol Commun Research Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuclein induced synucleinopathy in heterozygous mice transgenic for human mutant A53T α-synuclein (line M83). The same was the case when cerebellar extracts from a case of multiple system atrophy with type II α-synuclein filaments were administered intraperitoneally, intravenously or intramuscularly. We observed abundant immunoreactivity for pS129 α-synuclein in nerve cells and severe motor impairment, resulting in hindlimb paralysis and shortened lifespan. Filaments immunoreactive for pS129 α-synuclein were in evidence. A 70% loss of motor neurons was present five months after an intraperitoneal injection of assembled A53T α-synuclein or cerebellar extract with type II α-synuclein filaments from an individual with a neuropathologically confirmed diagnosis of multiple system atrophy. Microglial cells changed from a predominantly ramified to a dystrophic appearance. Taken together, these findings establish a close relationship between the formation of α-synuclein inclusions in nerve cells and neurodegeneration, accompanied by a shift in microglial cell morphology. Propagation of α-synuclein inclusions depended on the characteristics of both seeds and transgenically expressed protein. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01291-7. BioMed Central 2021-11-24 /pmc/articles/PMC8611835/ /pubmed/34819144 http://dx.doi.org/10.1186/s40478-021-01291-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Macdonald, Jennifer A.
Chen, John L.
Masuda-Suzukake, Masami
Schweighauser, Manuel
Jaunmuktane, Zane
Warner, Thomas
Holton, Janice L.
Grossman, Annabelle
Berks, Richard
Lavenir, Isabelle
Goedert, Michel
Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
title Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
title_full Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
title_fullStr Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
title_full_unstemmed Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
title_short Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α-synuclein seeds
title_sort assembly of α-synuclein and neurodegeneration in the central nervous system of heterozygous m83 mice following the peripheral administration of α-synuclein seeds
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611835/
https://www.ncbi.nlm.nih.gov/pubmed/34819144
http://dx.doi.org/10.1186/s40478-021-01291-7
work_keys_str_mv AT macdonaldjennifera assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT chenjohnl assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT masudasuzukakemasami assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT schweighausermanuel assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT jaunmuktanezane assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT warnerthomas assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT holtonjanicel assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT grossmanannabelle assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT berksrichard assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT lavenirisabelle assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds
AT goedertmichel assemblyofasynucleinandneurodegenerationinthecentralnervoussystemofheterozygousm83micefollowingtheperipheraladministrationofasynucleinseeds